Type 2 & other diabetes

Effect of ertugliflozin on left ventricular function in type 2 diabetes and pre-heart failure: the Ertu-GLS randomized clinical trial

Cardiovasc DiabetolPublished Randomised controlled trial

Authors' conclusion

This study demonstrated that ertugliflozin has beneficial effects on left ventricular function in individuals with type 2 diabetes and pre-heart failure, and it provided insights into potential underlying mechanisms.

Study context

Population
Individuals with T2D inadequately controlled with antidiabetic medications and pre-heart failure (left ventricular hypertrophy, E/e' >15, or impaired left ventricular global longitudinal strain (LVGLS)); mean age 63.9 ± 9.2 years; 38% womenrandomized 1:1
Participants
102 individuals
Comparison
Ertugliflozin 5 mg once daily vs placebo
Primary endpoint
Change in left ventricular global longitudinal strain (LVGLS)
Follow-up
24 weeks
Methodological detailsdouble-blind, placebo-controlled, 24-week
  • Double-blind
  • Placebo-controlled
  • 24-week

Primary result

As reported in the abstract

LVGLS, baseline to 24 weeks
Ertugliflozin: LVGLS from - 15.5 ± 3.1% to - 16.6 ± 2.8%
P = 0.004
Placebo: LVGLS from - 16.7 ± 2.7% to - 16.4 ± 2.6%
P = 0.509

Secondary outcomes

Left ventricular mass index (LVMI) and left ventricular ejection fraction (LVEF)

Improvements in LVMI and LVEF were also observed

Metabolic and other markers

Significant reductions in HbA1c, systolic blood pressure, whole-body and visceral fat, uric acid, proteinuria, NT-proBNP and lipoprotein(a)

ACE2 and angiotensin (1-7) levels (prespecified exploratory)

Correlation of ACE2 change with LVGLS change
r = 0.456, P < 0.001
Correlation of angiotensin (1-7) change with LVGLS change
r = 0.541, P < 0.001
Significantly increased with ertugliflozin vs placebo

Safety

Adverse events were similar between the two groups

Original publication

Effect of ertugliflozin on left ventricular function in type 2 diabetes and pre-heart failure: the Ertu-GLS randomized clinical trial. Cardiovasc Diabetol. Published 22 October 2024. doi:10.1186/s12933-024-02463-0

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.